GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Antithrombin Improves Fetal Condition in Severe
Pre-Eclampsia Before 32 Weeks of Gestation

http://tinyurl.com/26tdur

>>
J Obstet Gynaecol Res. 2008 Feb;34(1):34-9.

Sameshima H, Kodama Y, Ikenoue T, Kajiwara Y.

Department of Obstetrics and Gynecology and Perinatal Center, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Aim: To see if antithrombin (AT) supplementation improved fetal outcomes in early onset (<32 weeks) severe pre-eclampsia.

Methods: A subgroup re-analysis of an original randomized controlled trial of AT in pre-eclampsia between 24 and 35 weeks of gestation was performed. Either AT (3000 IU/day, n = 42) or placebo (Albumin 582 mg/day, n = 42) were administered for 7 days. Fetal weight gain, biophysical profile score and fetal heart rate monitoring were evaluated during the treatment week and until delivery. Comparisons were performed by intent-to-treat and relative risk (RR) and 95% Confidence Intervals (CI) were obtained.

Results: In each group, 27 women (64%) completed the allocated intervention. AT significantly decreased the worsening of the fetal biophysical profile score or fetal heart rate monitoring (RR 0.24, 95% CI 0.07-0.8), increased the incidence of estimated weight gain >15 g/day during the intervention week (3.1, 1.0-9.9), and prolonged gestational age to >/=34 weeks (3.6, 1.05-12.6), however infant mortality rates did not differ between the two groups. No adverse events related to AT were observed.

Conclusions: Supplementation of AT preserves fetal biophysical condition and weight gain in early onset severe pre-eclampsia and most likely prolongs pregnancies >/=34 weeks of gestation.
<<